ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Prostate cancer is highly treatable when detected early, as it carries a favourable prognosis. Therefore, awareness among ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

A new survey shows most construction workers delay or avoid prostate cancer screenings due to stigma and knowledge gaps. As ...

Nigeria records over 18,000 new prostate cancer cases annually, accounting for the highest cancer burden among men in the country.

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has ...

# A FORMER Royal Bahamas Defence Force officer facing up to 20 years in prison for his role in a major cocaine trafficking ...

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.